Pages Menu
Categories Menu

Posted by on Dec 9, 2014 in Foundation NewsLine |

Update from Genzyme on Acid Sphingomyelinase Deficiency (ASMD) Development Efforts ~ December 9th, 2014

Dear NNPDF Families and Friends,

The NNPDF Central Offices have been notified that Genzyme, a Sanofi Company, has released an official press announcement with details of the pediatric Phase 1 / 2 clinical trial & the adult Phase 2/3 of recombinant human acid sphingomyelinase (rhASM).

This is truly an exciting time for our Niemann-Pick Disease Type A & B (ASMD) families and community and the NNPDF looks forward to working with all involved in this matter as we work to ~ PERSEVERE in our Quest for a Cure! 
Share this!

Please spread the word!